{
  "symbol": "AMGN",
  "name": "Amgen",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "1992-01-02",
  "headquarters": "Thousand Oaks, California",
  "founded": "1980",
  "market_cap": 159771.27936,
  "pe_ratio": 27.110859,
  "forward_pe": 14.375182,
  "eps": 10.96,
  "revenue": 34126.000128,
  "profit_margin": 0.17386,
  "debt_to_equity": 924.456,
  "return_on_equity": 1.0567299,
  "dividend_yield": 3.41,
  "current_price": 297.135009765625,
  "year_high": 336.01082269666216,
  "year_low": 249.0688824790743,
  "price_change_1d": 0.045457833543771045,
  "price_change_1w": 2.2769589020058176,
  "price_change_1m": 3.4952990068872354,
  "description": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of re",
  "website": "https://www.amgen.com",
  "employees": 28000,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 314.27,
  "recommendation": 2.33333,
  "number_of_analysts": 28,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 400.0,
    "target_low": 185.0,
    "target_mean": 314.27,
    "target_median": 317.5
  },
  "last_updated": "2025-07-09T11:16:50.266129",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}